Structural and mechanistic basis of MICAL regulation
MICALs are a family of redox enzymes that directly bind and disassemble actin filaments. An increasing body of evidence in recent years indicates that MICALs play essential roles in many tissues for myriad activities requiring dis...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto MICAL
Duración del proyecto: 33 meses
Fecha Inicio: 2020-04-20
Fecha Fin: 2023-01-31
Líder del proyecto
UNIVERZITA KARLOVA
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
157K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
MICALs are a family of redox enzymes that directly bind and disassemble actin filaments. An increasing body of evidence in recent years indicates that MICALs play essential roles in many tissues for myriad activities requiring discrete changes in the cytoskeleton, including axon guidance, cell morphology, synaptogenesis and neuronal plasticity. MICALs are a component of classical signalling pathways and are best known as effectors for semaphorin-plexin signalling. Although the field has made enormous advances in understanding MICAL function at the level of genetic and cellular experiments, our knowledge of the molecular-level mechanisms of MICAL signalling in cytoskeletal dynamics remains poorly understood.
The overarching aim of this proposal is to understand the molecular mechanisms underlying MICAL signalling. I aim to address two fundamental and long-standing questions: (1) How do MICAL proteins precisely turn their activity on and off? (2) How do cytoplasmic segments of plexins pass the signal on to MICALs and what mechanisms control signalling? I will use a hybrid approach integrating single particle cryoEM with high-resolution X-ray crystallography to determine the overall architecture of MICAL and to elucidate molecular mechanisms of MICAL autoinhibition. In parallel, I will aim to determine the high-resolution structure of MICAL in complex with plexin to dissect molecular mechanisms of MICAL activation.
All previous attempts to tease out the mechanisms governing MICAL signalling failed because full-length MICAL is expressed at a relatively low level in many expression systems. The project will greatly benefit from my previously developed protocol describing the production of MICALs in milligram quantities. Our findings will reveal fundamental principles of MICAL signalling, which will open new possibilities in the manipulation of cell signalling, and pave the way towards the treatment of MICAL associated neurological disorders.